1. Volume 62, Issue 2, Pages 294-302 (February 2015)
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin 
Jordan J. Feld, Ira M. Jacobson, Donald M. Jensen, Graham R. Foster, Stanislas Pol, Edward Tam, Maciej Jablkowski, Hanna Berak, John M. Vierling, Eric M. Yoshida, Héctor R. Perez-Gomez, Astrid Scalori, Gregory J. Hooper, Jorge A. Tavel, Mercidita T. Navarro, Saba Shahdad, Rohit Kulkarni, Sophie Le Pogam, Isabel Nájera, Simon Eng, Chin Yin Lim, Nancy S. Shulman, Ellen S. Yetzer 
Journal of Hepatology 
Volume 62, Issue 2, Pages (February 2015)
DOI: /j.jhep
Copyright © 2014 European Association for the Study of the Liver Terms and Conditions

2. Fig. 1
Study design. Genotype 1a patients randomized to IFN-free treatment regimens were offered 24weeks of P/R in addition to their assigned treatment. DNVr, danoprevir/ritonavir 100/100mg; IFN, interferon; MCB, mericitabine 1000mg; P/R, PegIFN alfa-2a (180μg/week)/ribavirin (1000/1200dividedtwicedaily); RBV, ribavirin.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2014 European Association for the Study of the Liver Terms and Conditions

3. Fig. 2
Patient flow diagram and reasons for withdrawal from treatment. Study-specific rules were used to define completion for each group. The number of patients who completed treatment was based on the study specific rule to define completion for each group. ∗Genotype 1a patients were offered 24weeks of P/R in addition to their assigned treatment. DNVr, danoprevir/ritonavir; MCB, mericitabine; P/R, PegIFN alfa-2a/ribavirin; RBV, ribavirin.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2014 European Association for the Study of the Liver Terms and Conditions

4. Fig. 3
Virological response at the end of treatment (EOT) and after 24weeks of follow-up (SVR24). (A) In the overall population; (B) Genotype subtype 1a; (C) Genotype subtype 1b. ∗Genotype 1a patients were offered 24weeks of P/R in addition to their assigned treatment. DNVr, danoprevir/ritonavir; EOT, end of treatment; IFN, interferon; MCB, mericitabine; P/R, PegIFN alfa-2a/ribavirin; RBV, ribavirin; SVR24, sustained virological response (HCV RNA <25IU/ml) 24weeks after end-of-treatment.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2014 European Association for the Study of the Liver Terms and Conditions

5. Fig. 4
Relapse rates overall and stratified by HCV genotype subtype 1a and 1b. ∗Genotype 1a patients were offered 24weeks of P/R in addition to their assigned treatment. DNVr, danoprevir/ritonavir; IFN, interferon; MCB, mericitabine; P/R, PegIFN alfa-2a/ribavirin; RBV, ribavirin.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2014 European Association for the Study of the Liver Terms and Conditions

6. Journal of Hepatology 2015 62, 294-302DOI: (10. 1016/j. jhep. 2014. 09
Copyright © 2014 European Association for the Study of the Liver Terms and Conditions